Contains Begins With
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
1 2 3 4 5 6 7 8 9 A-M N-Z

#1413: Acetylcholine Receptor Modulating Autoabs COMPONENTS   Name Method Reference Range Units AChR Modulating Autoantibodies RIA < 20 %  SPECIMEN REQUIREMENTS   No Type Volume Temperature Container Type Instructions 1 - Primary Serum 2 (0.8) mL Ambient - 7 Day(s)/Refrigerated - 14 Day(s)/Frozen - 2 Month(s) Aliquot   GENERAL INFORMATION   Setup Schedule Thursday Reported Next day CPT Code 83519 Notes Prices might not include a handling fee. Test Performed At Specialty Laboratories, Inc. Clinical Utilities Myasthenia gravis (MG), the most common neuromuscular transmission disorder, is an antibody-mediated autoimmune disease that stems from a loss of acetylcholine receptors (AChR) at neuromuscular junctions. AChR autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR binding autoantibodies are present most frequently in MG and provide the most reliable information for diagnostic screening. A small portion of patients with early onset or ocular restricted MG may only have AChR modulating autoantibodies, thus if AChR binding autoantibodies are absent in a patient with weakness or ocular symptoms consistent with MG, AChR modulating autoantibodies should be ordered. AChR blocking autoantibodies are directed against the neurotransmitter-binding site and may be the only AChR autoantibody in about 1% of MG patients.